Windward Bio filed for a US initial public offering on Friday, becoming the latest ​drug developer seeking to capitalize on renewed ‌investor interest in biotech listings.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in